Encompass Health (EHC) Is Back In Focus, What Is Catching Attention?
Expansion into Bangor and what it could mean for Encompass Health stock
Encompass Health (EHC) has opened a 50 bed inpatient rehabilitation hospital in Bangor, Maine, extending its reach into a new market and adding capacity for complex recovery care.
Recent trading has been relatively calm, with the share price edging up 13.15% over the past 90 days to US$124.33 and Encompass Health’s 3 year total shareholder return of 96.21% pointing to strong longer term compounding. The Bangor opening arrives as that momentum builds, and this suggests that investors are weighing new capacity and geographic reach as potential drivers of future performance.
Scan more hospital operators with similar expansion stories by reviewing our curated list of list of solid balance sheet and fundamentals (25 results).
Encompass Health is adding fresh capacity in Bangor after a strong multi year share run, which raises a simple fork in the road for investors. Pay up now for that expansion or wait for a cheaper shot at it next.
Most Popular Narrative: 16% Undervalued
The strongest storyline around Encompass Health puts fair value at $148.17 per share, comfortably above the recent $124.33 close, and Bangor slots neatly into that capacity-led view.
Ongoing expansion of Encompass Health’s inpatient rehabilitation footprint through de novo hospitals, bed additions at high occupancy sites, and small format facilities, supported by a disclosed multi year pipeline and high returns on these projects, points to further discharge volume growth that can lift net operating revenue and EBITDA.
See why 6 investors see Encompass Health as 16% undervalued.
Result: Fair Value of $148.17 (UNDERVALUED)
Still, the Encompass Health story could be shaken if tougher Medicare Advantage pre authorizations squeeze discharge volumes or if new Bangor style projects ramp more slowly than expected.
Find out about the key risks to this Encompass Health narrative.
Another View on Encompass Health’s Valuation
On price targets and fair value, Encompass Health screens as undervalued against analyst models and the Simply Wall St fair value estimate. The P/E ratio tells a different story. At 20.3x, it sits above the 17.3x peer average, even though it is below the broader US Healthcare group at 24.5x.
The fair ratio is 24.9x, which is higher than where the stock trades today but closer to the industry level than to direct peers. That gap points to a simple question for investors: Does Encompass Health’s track record and hospital pipeline justify paying above similar operators, or does that introduce more valuation risk than you want?
To see how that price tag stacks up against peers and a fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages around Bangor, valuation, and future capacity only matter if you put numbers in context and decide what feels reasonable for you. For a sharper view of how Encompass Health’s potential upside compares with the key concerns flagged by investors, start with 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Encompass Health?
If Bangor and Encompass Health have sharpened your thinking, do not stop here. Use fresh filters to spot opportunities that better match your risk and return preferences.
- Target potential bargains by scanning companies with resilient fundamentals and valuation support through our 32 high quality undervalued stocks.
- Strengthen your income stream by focusing on reliable payouts using the 8 dividend fortresses.
- Dial down risk by concentrating on sturdier balance sheets and cleaner finances via the 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com